v3.26.1
Other (Income)/Deductions—Net - Schedule of Other (Income)/Deductions—Net (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Other Income and Expenses [Abstract]        
Interest income $ (113) $ (156) $ (228) $ (299)
Interest expense 667 654 1,336 1,308
Net interest expense 554 498 1,108 1,009
Net (gains)/losses recognized during the period on equity securities [1] 37 (75) 46 295
Net periodic benefit costs/(credits) other than service costs (83) (101) (155) (260)
Certain legal matters, net [2] 842 422 1,033 564
Certain asset impairments [3] 4,325 93 4,325 317
Net gain from the sale of investment in ViiV [4] (1,870) 0 (1,870) 0
Changes in fair value of contingent consideration liabilities [5] 255 34 550 42
Other, net [6] (344) (131) (460) (275)
Other (income)/deductions––net $ 3,716 $ 739 $ 4,577 $ 1,692
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The amounts for the second quarter and first six months of 2026 and 2025 primarily include certain product liability and other legal expenses.
[3] The amounts for the second quarter and first six months of 2026 represent intangible asset impairment charges associated with our Biopharma segment, composed of: (i) $3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results, and (ii) $525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S. The amount for the first six months of 2025 primarily included an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[4] See Note 2C.
[5] See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
[6] The amounts for the second quarter and first six months of 2026 include, among other things, dividend income of $98 million and $180 million, respectively, from our previous investment in ViiV. The amounts for the second quarter and first six months of 2025 included, among other things, dividend income of $73 million and $111 million, respectively, from our previous investment in ViiV.